Emcure Pharmaceuticals Limited (EMCURE) — Stock Analysis

Emcure Pharmaceuticals Limited (NSE: EMCURE), ISIN INE168P01015 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.

EMCURE last traded at ₹1904.80 (+0.70%), with a 52-week range of ₹1260.10 to ₹1957.80 (as of 30 Jul 2026).

Shareholding as of Jun 2026: promoters 77.83%, FIIs 4.88%, DIIs 8.46%, mutual funds 6.87%.

EquiSense Score (ECS): 78/100.

Data sourced from NSE and BSE filings. Educational — not investment advice.